Aviragen Therapeutics (AVIR) Tops Q2 EPS by 18c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.48), $0.18 better than the analyst estimate of ($0.66).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
• Elong Power files offering of up to 10.15M units at $0.985 each
• Benchmark Upgrades AbCellera Biologics (ABCL) to Buy